Health Care & Life Sciences » Biotechnology | Ampliphi Biosciences Corp.

Ampliphi Biosciences Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
325.00
409.00
475.00
260.00
115.00
Cost of Goods Sold (COGS) incl. D&A
82.00
-
-
-
-
Gross Income
243.00
-
-
-
-
SG&A Expense
12,679.00
12,497.00
10,083.00
13,722.00
10,097.00
EBIT
-
12,246.00
9,938.00
-
10,356.00
Unusual Expense
40,562.00
35,355.00
9,651.00
5,009.00
3,790.00
Non Operating Income/Expense
-
-
302.00
554.00
6.00
Interest Expense
2,863.00
-
-
-
-
Pretax Income
55,861.00
23,109.00
589.00
19,394.00
14,140.00
Income Tax
-
-
73.00
556.00
1,302.00
Consolidated Net Income
55,861.00
23,109.00
516.00
22,418.00
12,838.00
Net Income
55,861.00
23,109.00
516.00
22,418.00
12,838.00
Net Income After Extraordinaries
55,861.00
23,109.00
516.00
22,418.00
12,838.00
Net Income Available to Common
64,325.00
21,824.00
10,794.00
24,276.00
12,838.00
EPS (Basic)
320.00
35.00
19.90
246.70
2.18
Basic Shares Outstanding
202.40
374.70
541.10
98.40
6,387.40
EPS (Diluted)
317.81
33.72
19.95
246.75
2.18
Diluted Shares Outstanding
202.40
647.20
541.10
98.40
6,574.10
EBITDA
12,354.00
12,088.00
9,608.00
13,462.00
9,982.00
Other After Tax Income (Expense)
-
-
-
3,580.00
-
Preferred Dividends
8,464.00
1,285.00
10,278.00
1,858.00
-

About Ampliphi Biosciences

View Profile
Address
3579 Valley Centre Drive
San Diego California 92130
United States
Employees -
Website http://www.ampliphibio.com
Updated 09/14/2018
AmpliPhi Biosciences Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company was founded in March 1989 and is headquartered in San Diego, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.